Viracta Therapeutics, Inc.
VIRXDelisted Jul 10, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001061027
Viracta Therapeutics, Inc. was delisted on Jul 10, 2025; its insiders filed their last Form 4 on Nov 27, 2024; 32 institutions reported holding it in 13F filings for Q4 2024, worth $583.0K in total; no superinvestor held it.
13F holders, Q4 2025
Institutional positions in Viracta Therapeutics, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
VIRX is no longer listed, and 13F filings after Q4 2024 list far fewer holders. See Q4 2024
- Institutional holders
- 1
- +1 vs. Q3 2025
- Shares held
- 14
- +14 vs. Q3 2025
- Total value
- $0
- $0 vs. Q3 2025
- New holders
- 1
- 0 more added
- Sold out
- 0
- 0 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VIRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 1 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 7 | $3.80K |
| Q4 2024 | 32 | $583.0K |
| Q3 2024 | 38 | $1.29M |
| Q2 2024 | 40 | $4.91M |
| Q1 2024 | 40 | $9.58M |
| Q4 2023 | 42 | $5.56M |
| Q3 2023 | 42 | $10.1M |
| Q2 2023 | 41 | $14.1M |
| Q1 2023 | 48 | $19.4M |
| Q4 2022 | 56 | $18.1M |
| Q3 2022 | 59 | $52.8M |
| Q2 2022 | 63 | $44.2M |
| Q1 2022 | 69 | $62.2M |
| Q4 2021 | 69 | $51.8M |
| Q3 2021 | 68 | $124.6M |
| Q2 2021 | 63 | $151.8M |
| Q1 2021 | 50 | $92.0M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Viracta Therapeutics, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Motiv8 Investments LLC | 14 | $0 | 0.00% | +14 | New |